In the United
States, treatment costs of hospitalized MRSA patients run as high as $4.2
billion per year. For a patient who has an MRSA infection, a hospital stay is
likely to be three times longer than one by an uninfected patient, at three
times the cost. An MRSA-infected patient is also five times more likely to die
than an uninfected party.
Zenosense, a
healthcare technology company, is focused on developing a sensory device that
detects MRSA bacterial contamination in patients. To that end, Zenosense has
partnered with a respected sensor developer, Sgenia Group, to address this
multibillion-dollar medical issue. The sensory device will function as a “smoke
alarm” for MRSA, or uses an electronic nose to monitor and detect any airborne
Volatile Organic Compounds (VOC) signature emitted by MRSA. It will be deployed
for use in healthcare settings or other locations in which MRSA may pose a
medical risk. By detecting MRSA in its early stages of development, healthcare
providers will be able to minimize the heavy-handed costs of treatment
associated with late-stage MRSA patient infection.
At present, there
are devices for detection of incidences of this bacterial contamination, but
they pose significant expense burdens for healthcare providers and are bulky in
size, which minimizes advantages that could come with great setting mobility.
Zenosense’s coming innovation, on the other hand, will be a wearable device,
giving healthcare providers more flexibility in being able to deploy it to
different patient locations with greater ease. On top of its advantage of
mobility, the sensory device will make use of a technologically-potent, single
sensor that has an advanced VOC-detecting capability equivalent to tens of
thousands of sensors. While detection devices currently available cost around
$8,000 each, Zenosense anticipates being able to manufacture the device at less
than $100 per unit.
On top of MRSA
detection, Zenosense has also extended its agreement with Sgenia Group to
develop devices that detect VOC signatures given off by certain types of
cancer, such as lung cancer. Current medical estimates show many cases of lung
cancer being detected in its later stages, but earlier detection could lead to
a patient cure rate of 70 percent.
For more information
on the company visit www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment